Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.34 |
| ▸ | CCKBR | P32239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12843503 | 1.00 | IDO1 (0.38) | IDO1UCHL1CCNT1CDK9PIK3CD | |
| SCHEMBL1536437 | 1.00 | IDO1 (0.38) | IDO1UCHL1CCNT1CDK9PIK3CD | |
| SCHEMBL1536426 | 0.90 | CYP3A4 (0.41) | UCHL1PIK3CDHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL8176333 | 0.90 | CYP3A4 (0.41) | UCHL1PIK3CDHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL14617907 | 0.90 | CYP3A4 (0.41) | UCHL1PIK3CDHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL1536598 | 0.89 | P2RX3 (0.39) | UCHL1PIK3CDHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL13433609 | 0.89 | MCL1 (0.38) | UCHL1PIK3CDHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL8305805 | 0.89 | P2RX3 (0.39) | UCHL1PIK3CDHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL14038635 | 0.89 | P2RX3 (0.39) | UCHL1PIK3CDHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL8195379 | 0.88 | CYP3A4 (0.42) | UCHL1PIK3CDHCRTR1HCRTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9227940-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-01 | — | — | US | disclosed |
| US-8889871-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140163231-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130267713-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-10-10 | — | — | US | disclosed |
| US-8507722-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-8299094-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-7772180-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090274656-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| EP-2033654-A1 | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus | Bristol-Myers Squibb Company (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1629000-B1 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2009-02-18 | — | — | EP | disclosed |
| US-7449479-B2 | Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | IDO1 1960/4885UCHL1 588/4885CCNT1 1379/4885 |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | IDO1 1834/4885UCHL1 1551/4885CCNT1 668/4885 |
| US-20090274656-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, CTRB1 | IDO1 1834/4885UCHL1 1551/4885CCNT1 668/4885 |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | IDO1 1834/4885UCHL1 1551/4885CCNT1 668/4885 |
| US-20130267713-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | IDO1 1834/4885UCHL1 1551/4885CCNT1 668/4885 |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | IDO1 1834/4885UCHL1 1551/4885CCNT1 668/4885 |
| US-20140163231-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | IDO1 1834/4885UCHL1 1551/4885CCNT1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.